02616.HK
CStone Pharmaceuticals
HKSE · Healthcare · Biotechnology · CN
HKD 6.19
+0.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 600.2M | 269.6M | 407.2M | 463.8M | 481.4M |
| Cost of Revenue | 344.0M | 218.3M | 167.1M | 159.5M | 203.0M |
| Gross Profit | 256.1M | 51.2M | 240.2M | 304.3M | 278.4M |
| Operating Expenses | |||||
| R&D Expense | 530.0M | 311.5M | 134.7M | 527.8M | 614.2M |
| SG&A Expense | 355.1M | 172.4M | 166.9M | 248.1M | 390.5M |
| General & Admin Expense | 94.5M | 87.3M | 33.2M | 48.7M | 63.2M |
| Selling & Marketing Expense | 136.5M | 83.3M | 133.8M | 199.3M | 327.3M |
| Other Expenses | — | — | 30.2M | 134.0M | 185.9M |
| Total Operating Expenses | 885.1M | 483.9M | 331.8M | 909.9M | 1.2B |
| Cost and Expenses | 1.2B | 702.2M | 498.9M | 1.1B | 1.4B |
| Operating Income (EBIT) | (629.0M) | (432.6M) | (91.7M) | (605.6M) | (912.1M) |
| Non-Operating | |||||
| Interest Income | 25.2M | 10.1M | 12.7M | 24.9M | 9.7M |
| Interest Expense | 15.8M | 12.9M | 15.2M | 11.8M | 8.5M |
| Net Interest Income | 2.6M | (2.8M) | (2.5M) | 13.1M | 1.2M |
| Other Non-Op Income/Expense | (15.6M) | 8.7M | 485.0K | 238.3M | 9.5M |
| Non-Operating Income (excl Interest) | (29.7M) | (16.8M) | 3.7M | (224.4M) | — |
| EBT (Pre-Tax Income) | (644.6M) | (423.9M) | (91.2M) | (367.2M) | (902.7M) |
| Income Tax Expense | 13.1M | 13.1M | — | — | 61.9M |
| Bottom Line | |||||
| Net Income | (657.6M) | (437.0M) | (91.2M) | (367.2M) | (902.7M) |
| Earnings from Cont. Ops | (657.6M) | (437.0M) | (91.2M) | (367.2M) | (902.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (657.6M) | (437.0M) | (91.2M) | (367.2M) | (902.7M) |
| Per Share | |||||
| Basic EPS | (HK$0.45) | (HK$0.31) | (HK$0.07) | (HK$0.29) | (HK$0.77) |
| Diluted EPS | (HK$0.45) | (HK$0.31) | (HK$0.07) | (HK$0.29) | (HK$0.77) |
| Revenue Per Share | HK$0.39 | HK$0.19 | HK$0.32 | HK$0.37 | HK$0.41 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.4B | 1.3B | 1.3B | 1.2B |
| Diluted Shares Outstanding | 1.5B | 1.4B | 1.3B | 1.3B | 1.2B |
| Profitability Metrics | |||||
| EBITDA | (560.0M) | (403.8M) | (76.4M) | (297.2M) | (849.7M) |
| D&A | 39.3M | 12.0M | 18.9M | 58.2M | 44.5M |
| EBIT | (599.3M) | (415.8M) | (95.4M) | (355.4M) | (894.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026